Logo
E

Evommune

55 employees

Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life. Many immunology-focused medications give patients a temporary fix to a longer-term problem—addressing symptom control rather than the root cause of disease. Evommune is different. We strive to develop accessible innovations that are meant to address symptoms as well as help avoid disease progression and medical complications in the future.

Investor insights

Funding rounds participated in

$115M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2020

Funding rounds raised

Total raised

$115M

from 3 investors over 1 rounds

E

Evommune raised $115M on December 1, 2024

Investors: Sectoral Asset Management, RA Capital Management and + 16 Other investors

FAQ